Journal for immunotherapy of cancer · 2026
CD4+ T cells facilitate the RT-induced abscopal effect by promoting antigen cross-presentation to CD8+ T cells at unirradiated tumor sites.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rao Xi, Onyshchenko Kateryna, Wang Meidan, Luo Ren, Zhang Xuanwei, Wang Liqun, Kuhn Siegmar, Yang Yizhou, Gaedicke Simone, Grosu Anca-Ligia, Firat Elke, Niedermann Gabriele
Аннотация
BACKGROUND: The local effect of radiotherapy (RT) is enhanced by CD8+ T-cell responses elicited through dendritic cell (DC)-mediated cross-presentation of tumor antigens, facilitated by RT-induced damage-associated molecular patterns. The abscopal effect-regression of non-irradiated tumors-has been observed clinically, particularly in combination with immune checkpoint blockade, although it remains uncommon. To better understand how to enhance this effect, we investigated two RT/α-programmed death 1 (PD-1)-based triple combinations incorporating either α-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD122-targeted interleukin (IL)-2 complexes (IL-2c).
METHODS: We tested these regimens in B16 melanoma and C51 colon carcinoma models in mice with one irradiated and one non-irradiated tumor on opposite flanks.
RESULTS: In both models, RT/αPD-1/αCTLA-4 elicited a stronger abscopal response than RT/αPD-1/IL-2c. In the C51 model, RT/αPD-1/αCTLA-4 achieved a 61.5% abscopal cure rate, dependent on both CD8+ and CD4+ T cells. In contrast, the less effective RT/αPD-1/IL-2c response required only CD8+ T cells. The enhanced abscopal effect with RT/αPD-1/αCTLA-4 was associated with increased numbers, effector function, and reduced exhaustion of tumor-specific CD8+ tumor-infiltrating lymphocytes (TILs) and of CD4+ TILs, along with elevated CD80+CD86+ DCs in abscopal tumors, as shown by flow cytometry; immunofluorescence confirmed increased T-cell infiltration. CD4+ T-cell depletion during RT/αPD-1/αCTLA-4 treatment impaired abscopal but not irradiated tumor control, reducing infiltration of tumor-specific CD8+ T cells and conventional (c) DC1s, and diminishing cDC1-mediated cross-presentation in abscopal tumors. Activated CD4+ T cells upregulated CD80/CD86 on cDC1s and enhanced cross-presentation, partly via interferon-γ and tumor necrosis factor. Adoptively transferred tumor-specific CD8+ T cells from tumor-irradiated donors localized to unirradiated tumors and draining lymph nodes in αPD-1/αCTLA-4-treated recipients, but not in untreated or CD4+ T cell-depleted mice.
CONCLUSIONS: These results demonstrate that an RT-based combination therapy that robustly induces CD4+ T cells alongside CD8+ T cells can elicit a strong abscopal response and suggest that CD4+ effector T cells act at abscopal sites by promoting DC-mediated cross-presentation of tumor antigens to CD8+ T cells originating from the irradiated tumor.
METHODS: We tested these regimens in B16 melanoma and C51 colon carcinoma models in mice with one irradiated and one non-irradiated tumor on opposite flanks.
RESULTS: In both models, RT/αPD-1/αCTLA-4 elicited a stronger abscopal response than RT/αPD-1/IL-2c. In the C51 model, RT/αPD-1/αCTLA-4 achieved a 61.5% abscopal cure rate, dependent on both CD8+ and CD4+ T cells. In contrast, the less effective RT/αPD-1/IL-2c response required only CD8+ T cells. The enhanced abscopal effect with RT/αPD-1/αCTLA-4 was associated with increased numbers, effector function, and reduced exhaustion of tumor-specific CD8+ tumor-infiltrating lymphocytes (TILs) and of CD4+ TILs, along with elevated CD80+CD86+ DCs in abscopal tumors, as shown by flow cytometry; immunofluorescence confirmed increased T-cell infiltration. CD4+ T-cell depletion during RT/αPD-1/αCTLA-4 treatment impaired abscopal but not irradiated tumor control, reducing infiltration of tumor-specific CD8+ T cells and conventional (c) DC1s, and diminishing cDC1-mediated cross-presentation in abscopal tumors. Activated CD4+ T cells upregulated CD80/CD86 on cDC1s and enhanced cross-presentation, partly via interferon-γ and tumor necrosis factor. Adoptively transferred tumor-specific CD8+ T cells from tumor-irradiated donors localized to unirradiated tumors and draining lymph nodes in αPD-1/αCTLA-4-treated recipients, but not in untreated or CD4+ T cell-depleted mice.
CONCLUSIONS: These results demonstrate that an RT-based combination therapy that robustly induces CD4+ T cells alongside CD8+ T cells can elicit a strong abscopal response and suggest that CD4+ effector T cells act at abscopal sites by promoting DC-mediated cross-presentation of tumor antigens to CD8+ T cells originating from the irradiated tumor.